Masafumi Iijima
- Pharmacology top 1%
- Rheumatology top 2%
- Dermatology top 1%
- Immunology top 10%
- Pathology and Forensic Medicine top 5%
- Co-authors
- Koji HashimotoHideaki WatanabeHirohiko SuekiMikiko TohyamaYuji ShirakataTokio NakadaZenrō IkezawaTetsuo Shiohara
- Topics
- Contact Dermatitis and Allergies (16 papers)Drug-Induced Adverse Reactions (15 papers)Psoriasis: Treatment and Pathogenesis (6 papers)
- Cited by
- DermatologyPharmacologyRheumatology
- Journals
- The Journal of ImmunologyClinical Infectious DiseasesBiochemical and Biophysical Research Communications
- Partner nations
- JapanUnited StatesFrance
In The Last Decade
Masafumi Iijima
62 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 103
- Pharmacology 802
- Rheumatology 530
- Dermatology 474
- Immunology 406
- Pathology and Forensic Medicine 351
Countries citing papers authored by Masafumi Iijima
This map shows the geographic impact of Masafumi Iijima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masafumi Iijima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masafumi Iijima more than expected).
Fields of papers citing papers by Masafumi Iijima
This network shows the impact of papers produced by Masafumi Iijima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masafumi Iijima. The network helps show where Masafumi Iijima may publish in the future.
Co-authorship network of co-authors of Masafumi Iijima
This figure shows the co-authorship network connecting the top 25 collaborators of Masafumi Iijima. A scholar is included among the top collaborators of Masafumi Iijima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masafumi Iijima. Masafumi Iijima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 91 | |
| 2 | 24 | |
| 3 | 25 | |
| 4 | 25 | |
| 5 | 6 | |
| 6 | 36 | |
| 7 | 72 | |
| 8 | 21 | |
| 9 | 4 | |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 10 | |
| 13 | 3 | |
| 14 | 1 | |
| 15 | 2 | |
| 16 | 1 | |
| 17 | 2 | |
| 18 | 1 | |
| 19 | 3 | |
| 20 | 1 |
About Masafumi Iijima
Masafumi Iijima is a scholar working on Dermatology, Immunology and Allergy and Pharmacology, having authored 66 papers that have together received 1.6k indexed citations. Recurring topics across this work include Contact Dermatitis and Allergies (16 papers), Drug-Induced Adverse Reactions (15 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). The work is most often cited by research in Dermatology (474 citations), Pharmacology (802 citations) and Rheumatology (530 citations). Masafumi Iijima has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Koji Hashimoto, Hideaki Watanabe, Hirohiko Sueki, Mikiko Tohyama, Yuji Shirakata, Tokio Nakada, Zenrō Ikezawa, Tetsuo Shiohara, Stephen I. Katz and Naoyuki Kamatani. Their work appears in journals such as The Journal of Immunology, Clinical Infectious Diseases and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.